BIORA THERAPEUTICS, INC. Quarterly Operating Income (Loss) in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Biora Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2019 to Q3 2024.
  • Biora Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$16.2M, a 30.4% increase year-over-year.
  • Biora Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$60.9M, a 9.92% increase year-over-year.
  • Biora Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$67.1M, a 8.68% decline from 2022.
  • Biora Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$61.8M, a 47.6% increase from 2021.
  • Biora Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$118M, a 9.5% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$60.9M -$16.2M +$7.09M +30.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$68M -$15.8M -$852K -5.71% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 -$67.1M -$15.5M +$28K +0.18% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$67.1M -$13.3M +$432K +3.14% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-01
Q3 2023 -$67.6M -$23.3M -$9.43M -67.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$58.1M -$14.9M -$724K -5.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 -$57.4M -$15.5M +$4.36M +21.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$61.8M -$13.8M +$6.38M +31.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-01
Q3 2022 -$68.2M -$13.9M +$16.7M +54.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$84.8M -$14.2M +$21.4M +60.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$106M -$19.9M +$11.6M +36.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$118M -$20.2M +$31.2M +60.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 -$149M -$30.6M +$105K +0.34% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$149M -$35.7M -$9.17M -34.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$140M -$31.5M +$21.1M +40.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$161M -$51.4M -$2.4M -4.9% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-18
Q3 2020 -$159M -$30.7M +$24.2M +44.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$183M -$26.5M -$12.2M -85.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$171M -$52.5M -$30.5M -139% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 -$140M -$49M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-18
Q3 2019 -$54.8M Jul 1, 2019 Sep 30, 2019 10-K 2021-03-18
Q2 2019 -$14.3M Apr 1, 2019 Jun 30, 2019 10-K 2021-03-18
Q1 2019 -$22M Jan 1, 2019 Mar 31, 2019 10-K 2021-03-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.